Y-mAbs Therapeutics uses Alphalyse’s mAb analysis services to investigate batch differences of their mAbs. The results help them optimize their purification steps and are also helpful for regulatory documentation.
Y-mAbs Therapeutics, Inc (Y-mAbs) is a late-stage clinical biopharmaceutical company listed on NASDAQ. The company devotes its energy to cancer treatment with antibody-based therapeutics. At the moment, they have two pivotal-stage product candidates – Naxitamab and Omburtamab.
Detailed mAb analysis service to optimize purification steps
Y-mAbs needs protein analysis services on an ongoing basis, including mAb characterization. They use them to support the development of new therapeutic products based on monoclonal antibodies.
After searching the market for possible lab partners, Y-mAbs collaborated with Alphalyse. Here they get top-of-the-line LC-MS analyses, including peptide mapping, intact mass analysis, and analysis of post-translation modifications, such as disulfide bridges and glycosylations.
The client uses the results for comparing various batches and optimizing purification steps. Furthermore, they provide a basis for regulatory documentation.
If you want to know more about our various mAb analysis services, you can learn more on this page dedicated to antibody analysis. You are, of course, also welcome to contact us to get advice specific to your project.